Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20:71–88. https://doi.org/10.1038/s41576-018-0071-5.

Article  CAS  PubMed  Google Scholar 

Patelli G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Bardelli A, Siena S, Marsoni S. Clinical utility and future perspectives of liquid biopsy in colorectal cancer. Commun Med (lond). 2025;5:137. https://doi.org/10.1038/s43856-025-00852-4.

Article  CAS  PubMed  Google Scholar 

Hoang T, Choi MK, Oh JH, Kim J. Utility of circulating tumor DNA to detect minimal residual disease in colorectal cancer: A systematic review and network meta-analysis. Int J Cancer. 2025;157:722–40. https://doi.org/10.1002/ijc.35442.

Article  CAS  PubMed  Google Scholar 

Kajiwara Y, Ueno H. Essential updates 2022–2023: Surgical and adjuvant therapies for locally advanced colorectal cancer. Ann Gastroenterol Surg. 2024;8:977–86. https://doi.org/10.1002/ags3.12853.

Article  PubMed  PubMed Central  Google Scholar 

Pinheiro M, Moreira DN, Ghidini M. Colon and rectal cancer: An emergent public health problem. World J Gastroenterol. 2024;30:644–51. https://doi.org/10.3748/wjg.v30.i7.644.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruiz-Banobre J, Goel A. Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time? JAMA Oncol. 2023;9:763–4. https://doi.org/10.1001/jamaoncol.2023.0329.

Article  PubMed  Google Scholar 

Mo S, Ye L, Wang D, Han L, Zhou S, Wang H, Dai W, Wang Y, Luo W, Wang R, et al. Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation. JAMA Oncol. 2023;9:770–8. https://doi.org/10.1001/jamaoncol.2023.0425.

Article  PubMed  PubMed Central  Google Scholar 

Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, Kato K, Kotaka M, Kagawa Y, Yeh KH, et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30:3272–83. https://doi.org/10.1038/s41591-024-03254-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pellatt AJ, Bent A, Hornstein N, Parseghian C, Huey R, Raghav K, Morris V, Overman M, Morelli P, Willis J, et al. Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT–TT. Jco Precis Oncol. 2025;9:e2500142. https://doi.org/10.1200/PO-25-00142.

Article  PubMed  Google Scholar 

Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, Wong R, Shapiro J, Lee M, Harris S, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022;386:2261–72. https://doi.org/10.1056/NEJMoa2200075.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, Shapiro JD, Harris SJ, Khattak A, Burge ME, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5‑year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31:1509–18. https://doi.org/10.1038/s41591-025-03579-w.

Article  CAS  PubMed  Google Scholar 

Burtin F, Elias L, Hinz S, Forster M, Hildebrandt G, Frerker B, Bock F. ctDNA responds to neoadjuvant treatment in locally advanced rectal cancer. J Cancer Res Clin Oncol. 2024;150:428. https://doi.org/10.1007/s00432-024-05944-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou J, Wang C, Lin G, Xiao Y, Jia W, Xiao G, Liu Q, Wu B, Wu A, Qiu H, et al. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study. Clin Cancer Res. 2021;27:301–10. https://doi.org/10.1158/1078-0432.CCR-20-2299.

Article  CAS  PubMed  Google Scholar 

Akiyoshi T, Shinozaki E, Maeda Y, Taguchi S, Chino A, Hanaoka Y, Toda S, Matoba S, Tin A, Spickard E, et al. Circulating Tumor DNA Longitudinal Analysis During Total Neoadjuvant Therapy and Non-operative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial. Clin Cancer Res. 2025; https://doi.org/10.1158/1078-0432.CCR-25-1242.

Article  PubMed  Google Scholar 

Kim JK, Alden AJ, Knaus S, Thakkar R, Moudgill L, Chudzinski A, Cavallaro P, Martinez C, Bennett RD, Marcet J. Circulating Tumor DNA Detects Minimal Residual Disease in Patients with Locally Advanced Rectal Cancer After Total Neoadjuvant Therapy. Cancers (basel). 2025; https://doi.org/10.3390/cancers17152560.

Article  PubMed  PubMed Central  Google Scholar 

Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, Kanter K, Fish MG, Fosbenner KD, Miao B, et al. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021;27:5586–94. https://doi.org/10.1158/1078-0432.CCR-21-0410.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019;5:1124–31. https://doi.org/10.1001/jamaoncol.2019.0528.

Article  PubMed  PubMed Central  Google Scholar 

Holz A, Paul B, Zapf A, Pantel K, Joosse SA. Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis. Cancer Treat Rev. 2025;139:102999. https://doi.org/10.1016/j.ctrv.2025.102999.

Article  CAS  PubMed  Google Scholar 

Ciardiello D, Boscolo Bielo L, Napolitano S, Martinelli E, Troiani T, Nicastro A, Latiano TP, Parente P, Maiello E, Avallone A, et al. Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF(V600E) wild-type metastatic colorectal cancer in the CAPRI 2‑GOIM trial. Ann Oncol. 2024;35:1105–15. https://doi.org/10.1016/j.annonc.2024.08.2334.

Article  CAS  PubMed  Google Scholar 

Wang W, Huang Y, Kong J, Lu L, Liao Q, Zhu J, Wang T, Yan L, Dai M, Chen Z, et al. Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer. Clin Transl Oncol. 2024;26:1976–87. https://doi.org/10.1007/s12094-024-03422-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakamura Y, Olsen S, Zhang N, Liao J, Yoshino T. Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database. Curr Oncol. 2022;29:3433–48. https://doi.org/10.3390/curroncol29050277.

Article  PubMed  PubMed Central  Google Scholar 

Ahn DH, Barzi A, Ridinger M, Samuelsz E, Subramanian RA, Croucher PJP, Smeal T, Kabbinavar FF, Lenz HJ. Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clin Cancer Res. 2024;30:2039–47. https://doi.org/10.1158/1078-0432.CCR-23-3053.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moser T, Waldispuehl-Geigl J, Belic J, Weber S, Zhou Q, Hasenleithner SO, Graf R, Terzic JA, Posch F, Sill H, et al. On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer. Npj Precis Oncol. 2020;4:30. https://doi.org/10.1038/s41698-020-00134-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, Ferruz N, Russo M, Misale S, Gonzalez I, et al. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clin Cancer Res. 2015;21:2157–66. https://doi.org/10.1158/1078-0432.CCR-14-2821.

Article  CAS  PubMed  Google Scholar 

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6. https://doi.org/10.1038/nature11156.

Article  CAS  PubMed  PubMed Central